Halozyme Therapeutics, Inc.

NasdaqGS:HALO Stock Report

Market Cap: US$5.2b

Halozyme Therapeutics Balance Sheet Health

Financial Health criteria checks 3/6

Halozyme Therapeutics has a total shareholder equity of $83.8M and total debt of $1.5B, which brings its debt-to-equity ratio to 1788.9%. Its total assets and total liabilities are $1.7B and $1.6B respectively. Halozyme Therapeutics's EBIT is $340.1M making its interest coverage ratio 38.8. It has cash and short-term investments of $336.0M.

Key information

1,788.9%

Debt to equity ratio

US$1.50b

Debt

Interest coverage ratio38.8x
CashUS$336.00m
EquityUS$83.81m
Total liabilitiesUS$1.65b
Total assetsUS$1.73b

Recent financial health updates

Recent updates

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Mar 15
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09
We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28
Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09
Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Oct 24
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today

Sep 08
Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today

Halozyme Therapeutics raises $625M through convertible senior notes due 2028

Aug 16

Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off

Aug 03

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jul 26
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Jun 10
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme: Antares Pharma Bolsters Growth Prospects

May 19

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Apr 25
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Financial Position Analysis

Short Term Liabilities: HALO's short term assets ($746.4M) exceed its short term liabilities ($112.5M).

Long Term Liabilities: HALO's short term assets ($746.4M) do not cover its long term liabilities ($1.5B).


Debt to Equity History and Analysis

Debt Level: HALO's net debt to equity ratio (1388%) is considered high.

Reducing Debt: HALO's debt to equity ratio has increased from 50.8% to 1788.9% over the past 5 years.

Debt Coverage: HALO's debt is well covered by operating cash flow (25.9%).

Interest Coverage: HALO's interest payments on its debt are well covered by EBIT (38.8x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.